A phase I safety and immunogenicity trial of an alphavirus replicon HIV subtype C gag vaccine (AVX101, Alphavax, Inc.) in healthy HIV-1 uninfected adult volunteers

Trial Profile

A phase I safety and immunogenicity trial of an alphavirus replicon HIV subtype C gag vaccine (AVX101, Alphavax, Inc.) in healthy HIV-1 uninfected adult volunteers

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2012

At a glance

  • Drugs AVX 101 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jun 2012 Actual end date (1 Jul 2005) added as reported by ClinicalTrials.gov.
    • 29 Jun 2012 Actual initiation date (1 Jul 2003), drug company (AlphaVax), additional lead trial centre and actual patient number 48 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top